< 生产厂家价格 >

氯帕胺

氯帕胺用途

Clopamide 是一种具有口服活性的噻嗪类利尿剂,可抑制钠耦合的氯离子共转运蛋白 SLC12A3。Clopamide 可用于高血压和心力衰竭的研究。

点击显示

氯帕胺名称

[ CAS 号 ]:
636-54-4

[ 中文名 ]:
氯帕胺

[ 英文名 ]:
Clopamide

[中文别名 ]:

氯哌酰胺

[英文别名 ]:

EINECS 211-261-7
Brinaldix
DT-327
CLOPAMIDUM
ChlosudiMepriMyl
Adurix
MFCD00941495
Aquex

氯帕胺生物活性

[ 描述 ]:

Clopamide 是一种具有口服活性的噻嗪类利尿剂,可抑制钠耦合的氯离子共转运蛋白 SLC12A3。Clopamide 可用于高血压和心力衰竭的研究。

[ 相关类别 ]:

研究领域 >> 心血管疾病

信号通路 >> 其他 >> 其他

研究领域 >> 代谢疾病

[体外研究]

氯丙胺由肾小管细胞主动分泌,真正的肾小管排泄分数(TTEF)值为10%[3]。

[体内研究]

清醒犬口服氯丙胺(0.5 mg/kg)和同时局部输注环孢素-A(1-10μg/min)后,缓激肽的静脉收缩反应减弱[4]。

[参考文献]

[1]. J J McNeil, et al. Clopamide: plasma concentrations and diuretic effect in humans. Clin Pharmacol Ther. 1987 Sep;42(3):299-304.

[2]. Yoshiteru Noutoshi, et al. Diuretics prime plant immunity in Arabidopsis thaliana. PLoS One. 2012;7(10):e48443.

[3]. B Odlind, et al. Renal tubular secretion and effects of chlorothiazide, hydrochlorothiazide and clopamide: a study in the avian kidney. Acta Pharmacol Toxicol (Copenh). 1982 Sep;51(3):187-97.

[4]. E Müller-Schweinitzer, et al. Interaction of cyclosporine-A with the renin-angiotensin system in canine veins. Naunyn Schmiedebergs Arch Pharmacol. 1989 Aug;340(2):252-7.

氯帕胺物理化学性质

[ 密度 ]:
1.4±0.1 g/cm3

[ 熔点 ]:
244-246ºC

[ 分子式 ]:
C₁₄H₂₀ClN₃O₃S

[ 分子量 ]:
345.845

[ 精确质量 ]:
345.091400

[ PSA ]:
100.88000

[ LogP ]:
1.59

[ 外观性状 ]:
白色至淡黄色结晶粉末

[ 折射率 ]:
1.613

[ 储存条件 ]:
2-8°C

氯帕胺安全信息

[ 符号 ]:

GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H317-H334

[ 警示性声明 ]:
P261-P280-P284-P304 + P340-P342 + P311

[ 危害码 (欧洲) ]:
Xn

[ 风险声明 (欧洲) ]:
R42/43

[ 安全声明 (欧洲) ]:
36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ 海关编码 ]:
2935009090

氯帕胺海关

[ 海关编码 ]: 2935009090

[ 中文概述 ]:
2935009090 其他磺（酰）胺. 增值税率:17.0% 退税率:9.0% 监管条件:无最惠国关税:6.5% 普通关税:35.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%

氯帕胺文献

Ultra high performance supercritical fluid chromatography coupled with tandem mass spectrometry for screening of doping agents. I: Investigation of mobile phase and MS conditions.

Anal. Chim. Acta 853 , 637-46, (2014)

The conditions for the analysis of selected doping substances by UHPSFC-MS/MS were optimized to ensure suitable peak shapes and maximized MS responses. A representative mixture of 31 acidic and basic ...

Ultra high performance supercritical fluid chromatography coupled with tandem mass spectrometry for screening of doping agents. II: Analysis of biological samples.

Anal. Chim. Acta 853 , 647-59, (2014)

The potential and applicability of UHPSFC-MS/MS for anti-doping screening in urine samples were tested for the first time. For this purpose, a group of 110 doping agents with diverse physicochemical p...

Effects of pindolol, or a pindolol/clopamide combination preparation, on plasma lipid levels in essential hypertension. Hunter Hypertension Research Group.

Med. J. Aust. 150(11) , 646, 648, 651-2, (1989)

In an open study that was conducted in general practice, 22 patients with previously-untreated mild hypertension received an average daily dose of 11.7 mg of pindolol over a 50-week study period. The ...

更多文献

氯帕胺